Clinical Trials
11 trialsNCT03323658 2023-01-10
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01578499 2021-01-05
ALCANZA
Takeda
Phase 3 Completed
NCT00411632 2020-01-29
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01007448 2019-11-12
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
Phase 4 Completed
NCT00125359 2019-01-08
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00125372 2019-01-08
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT00425477 2018-10-05
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00255801 2018-08-16
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00178841 2016-02-17
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Vanderbilt University
Phase 2 Completed
NCT00718770 2014-01-17
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
NCT00050960 2012-07-13
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Eisai Inc.
Phase 3 Completed